Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: A pilot study

Primary Care Respiratory Journal

Volumn 21, Issue 1, 2012, Pages 28-34

  Turton, James A ^a   Glasgow, Nicholas J ^a   Brannan, John D ^b  

^a The Australian National University   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Asthma control; Bronchial hyperresponsiveness; Inhaled corticosteroids; Mannitol; Primary care; Treatment

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; MANNITOL; SALBUTAMOL; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE MANAGEMENT; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RESPIRATORY TRACT PARAMETERS;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; FEASIBILITY STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MANNITOL; MIDDLE AGED; PILOT PROJECTS; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 84857978709     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00079     Document Type: Article

References (26)

1. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999;103(2 Pt 1):232-7. http://dx.doi.org/10.1016/S0091-6749(99)70496-3
2. Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51(5):496-502. http://dx.doi.org/10.1136/thx.51.5.496
3. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008;31(2):320-5. http://dx.doi.org/10.1183/09031936.00039707
4. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40-7. http://dx.doi.org/10.1016/j.jaci.2004.04.042
5. Horne R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 2007;7:8. http://dx.doi.org/10.1186/1471-2466-7-8
6. Ruffin RE. Time to rethink asthma management. Thorax 2009;64(12):1013-14. http://dx.doi.org/10.1136/thx.2009.124040
7. Hancox RJ, Le Souef PN, Anderson GP, Reddel HK, Chang AB, Beasley R. Asthma: time to confront some inconvenient truths. Respirology 2010;15(2):194-201. http://dx.doi.org/10.1111/j.1440-1843.2009.01700.x
8. Global Initiative for Asthma. Revised 2007. Global strategy for asthma management and prevention. National Institutes of Health, Lung and Blood Institute. NHLBI/WHO Workshop Report. Medical Communication Resources Inc, Bethesda, Maryland. pp 16-19. Available from: http://www.ginasthma.org.
9. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180(1):59-99. http://dx.doi.org/10.1164/rccm.200801-060ST
10. Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005;6:144.
11. Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009;10:4.
12. Brannan JD, Gulliksson M, Anderson SD, Chew N, Seale JP, Kumlin M. Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing. Eur Respir J 2006;27(5):944-50.
13. Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients.Clin Exp Allergy 2008;38(1):43-50. http://dx.doi.org/10.1111/j.1365-2222.2007.02878.x
14. Brannan JD, Koskela H, Anderson SD, Chan H-K. Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology 2002;7(1):37-44. http://dx.doi.org/10.1046/j.1440-1843.2002.00357.x
15. Koskela H, Hyvärinen L, Brannan JD, Chan H-K, Anderson SD. Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. Chest 2003;124(4):1341-9. http://dx.doi.org/10.1378/chest.124.4.1341
16. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbations during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163(2):406-12.
17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159(1):179-87.
18. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47(2):76-83. http://dx.doi.org/10.1136/thx.47.2.76
19. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14(4):902-07. http://dx.doi.org/10.1034/j.1399-3003.1999.14d29.x
20. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100(4):616-21. http://dx.doi.org/10.1016/j.rmed.2005.08.012
21. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999;14(5):1038-43. http://dx.doi.org/10.1183/09031936.99.14510389
22. Brannan JD. Bronchial hyperresponsiveness in the assessment of asthma control. Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138(2 Suppl):11S-7S. http://dx.doi.org/10.1378/chest.10-0231
23. Veitch C, Hollins J, Worley P, Mitchell G. General practice research. Problems and solutions in participant recruitment and retention. Aust Fam Physician 2001;30(4):399-406.
24. Aaron SD, Vandemheen KL, Boulet LP, et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 2008;179(11):1121-31. http://dx.doi.org/10.1503/cmaj.081332
25. Diette GB, Patino CM, Merriman B, et al. Patient factors that physicians use to assign asthma treatment. Arch Intern Med 2007;167(13):1360-6. http://dx.doi.org/10.1001/archinte.167.13.1360
26. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114(6):1288-93. http://dx.doi.org/10.1016/j.jaci.2004.09.028